Document:

FOURTH WAIVER AND AMENDMENT
                           ---------------------------

     This FOURTH WAIVER AND AMENDMENT ("Amendment") is made effective the 1st
day of June, 2009, by and between CDEX Inc., a Nevada corporation ("Company"),
and GEMINI MASTER FUND, LTD., a Cayman Islands company ("Holder").

                              W I T N E S S E T H:
                              - - - - - - - - - -

          WHEREAS, pursuant to that certain Securities Purchase Agreement
("Purchase Agreement") dated as of June 25, 2008 by and between the Company and
the Holder, on or about such date the Company sold and issued to the Holder (i)
a 12% Senior Convertible Note ("Note"), which Note is convertible into shares of
common stock of the Company, $0.005 par value per share ("Common Stock"), and
(ii) a Common Stock Purchase Warrant to purchase up to 2,717,391 shares of
Common Stock ("Warrant");

          WHEREAS, by agreements dated December 18, 2008 and February 1 and May
1, 2009, entitled Waiver and Amendment ("First Amendment"), Second Waiver and
Amendment ("Second Amendment") and Third Waiver and Amendment ("Third
Amendment"), respectively, the Transaction Documents were amended; capitalized
terms used herein but not otherwise defined herein shall have the meanings set
forth in the Purchase Agreement, the Note, the Warrant, the First Amendment, the
Second Amendment, or the Third Amendment as the case may be: and

          WHEREAS, the Company wishes to extend the Extended Waiver Period
without the anti-dilution adjustments applying as set forth in the Transaction
Documents in certain circumstances and to delay payments to Holder for interest
and Monthly Redemption Amounts due on and from June 1, 2009 through and
including October 1, 2009 under the Note and subsequent amendments until October
1, 2009.

          NOW THEREFORE, in consideration of the foregoing premises and the
mutual covenants set forth in this Amendment, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:

     1. Subsequent Issuance Waivers--Common Stock Issuances. Notwithstanding
anything contained in the Transaction Documents, including the First, Second and
Third Amendments thereto, the Extended Waiver Period defined in the Second
Amendment is hereby extended until October 1, 2009.

     2. January, February, March, April, May, June and July Monthly Redemption.
The Holder hereby agrees that the Company, at its option, may delay payment of
the interest and Monthly Redemption Amounts which have not previously been
converted to Common Stock due on June 1, 2009, July 1, 2009, August 1, 2009 and
September 1, 2009 until October 1, 2009 (in which case on October 1, 2009 the
Company shall pay the Monthly Redemption Amounts due on June 1, 2009 and the
payments due on July 1, August 1, September 1 and October 1, 2009, i.e., a total
of $517,984.00, consisting of $447,240.42 principal and $70,743.58 interest
accruing under the Note from March 16, 2009 through October 1, 2009). The Holder
at its option may at any time and from time to time convert any or all of said
$517,984.00 in principal and interest under the Note into Common Stock of the

                                       1
<PAGE>

Company at a conversion price equal to $0.10 per share. The Company shall give
the Holder at least 5 days prior written notice of any early payment of any
portion of such amount, in which case such amount elected to be prepaid shall be
due and payable on such early payment date elected.

     3. Exercise Price Reduction. In consideration for the waivers and
extensions granted by the Holder herein, the Exercise Price under the Warrant is
hereby reduced to $0.15 effective as of the date hereof. Promptly following the
date hereof the Company shall replace the existing Warrant with a new Warrant
identical in all respects except with the reduction of the Exercise Price as set
forth herein.

     4. Rule 144. The Company acknowledges and agrees that, for purposes of Rule
144 promulgated under the Securities Act of 1933, as amended ("Securities Act"),
the holding period for the shares of Common Stock issuable upon conversion or
cashless exercise of, or otherwise pursuant to, the Note and/or Warrant, shall
have commenced on June 25, 2008 (the date of original issuance of the Note and
the Warrant), notwithstanding this Amendment. Without limiting the foregoing, if
at any time it is determined that such holding period does not relate back to
such date, the Company will promptly cause the registration of all such
underlying shares under the Securities Act (without regard to any beneficial
ownership or issuance limitations contained in the Note and/or Warrant). In
connection with any registration of shares of Common Stock pursuant to this
Section, the Company and the Holder shall enter into a registration rights
agreement containing customary and reasonable provisions regarding the
registration of securities under the Securities Act.

     5. Disclosure. To the extent the transactions contemplated by this
Amendment constitute material non-public information concerning the Company or
are otherwise required to be publicly disclosed under the Securities Exchange
Act of 1934, as amended, and the rules promulgated thereunder, the Company
shall, within three (3) business days following the date hereof, issue a press
release and/or Current Report on Form 8-K disclosing the material terms of the
transactions contemplated hereby. The Company and the Holder shall consult with
each other in issuing any other press releases with respect to the transactions
contemplated hereby.

     6. Miscellaneous.

          (a) Full Force and Effect. Except as otherwise expressly provided
     herein, each of the Purchase Agreement, the Note, the Warrant, the First
     Amendment, the Second Amendment, the Third Amendment and the other
     agreements and transactions contemplated thereby ("Transaction Documents")
     shall remain in full force and effect. Except for the waiver and
     modifications contained herein, this Amendment shall not in any way waive
     or prejudice any of the rights or obligations of the Holder or the Company
     under the Transaction Documents, under any law, in equity or otherwise, and
     such modifications shall not constitute a waiver or modification of any
     other provision of the Transaction Documents nor a waiver or modification
     of any subsequent default or breach of any obligation of the Company or of
     any subsequent right of the Holder.

          (b) Governing Law. This Amendment shall be governed by and construed
     in accordance with the internal laws of the State of New York.

                                       2
<PAGE>

          (c) Counterparts. This Amendment may be executed in any number of
     counterparts, each of which will be deemed an original, but all of which
     together will constitute one and the same instrument. This Amendment may be
     executed by facsimile or by email of a digital image format or portable
     document format of the signature page hereto.

     IN WITNESS WHEREOF, each of the parties hereto has caused this Amendment to
be duly executed effective the date first written above.

                                    CDEX INC.

                                    By:
                                    --------------------------------------------
                                    Name:  Malcolm H. Philips, Jr.
                                    Title: CEO
                                    Date:  June 5, 2009

                                    GEMINI MASTER FUND, LTD.
                                    By:    GEMINI STRATEGIES, LLC,
                                           as investment manager

                                           By:
                                    --------------------------------------------
                                           Name:  Steven Winters
                                           Title: President
                                           Date:  June 5, 2009

                                       3ex10-1.htm

    
      Exhibit
10.1 – Non exclusive license agreement between Materials and NASA

      

      LICENSE
AGREEMENT

      

      

      

      

      

      NATIONAL
AERONAUTICS AND SPACE ADMINISTRATION

      

      

      

      

      

      AND

      

      

      

      

      

       

      NANOTAILOR,
INC.

       

      

      

      

      

      

      

      

       

      NONEXCLUSIVE
LICENSE AGREEMENT DN-

      

      

      

      

      

      

      

       

      LICENSE
COMMENCEMENT DATE:

      

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      TABLE
OF CONTENTS

      

      
        
          

          
            	
                    ARTICLE
      NO.

                  	 
      	
                    PAGE

                  
	 
      	 
      	 
      
	 
      	
                    Preamble

                  	
                    4

                  
	 
      	 
      	 
      
	
                    I

                  	
                    Definitions

                  	
                    5

                  
	 
      	 
      	 
      
	
                    II

                  	
                    License
      Grant

                  	
                    7

                  
	 
      	 
      	 
      
	
                    III

                  	
                    Sublicenses

                  	
                    8

                  
	 
      	 
      	 
      
	
                    IV

                  	
                    Term
      of License

                  	
                    8

                  
	 
      	 
      	 
      
	
                    V

                  	
                    Practical
      Application

                  	
                    9

                  
	 
      	 
      	 
      
	
                    VI

                  	
                    United
      States Manufacture

                  	
                    9

                  
	 
      	 
      	 
      
	
                    VII

                  	
                    Royalty
      and Payment

                  	
                    9

                  
	 
      	 
      	 
      
	
                    VIII

                  	
                    Reports

                  	
                    11

                  
	 
      	 
      	 
      
	
                    IX

                  	
                    Audit
      Rights

                  	
                    13

                  
	 
      	 
      	 
      
	
                    X

                  	
                    Marking

                  	
                    14

                  
	 
      	 
      	 
      
	
                    XI

                  	
                    Use
      of the NASA Name

                  	
                    14

                  
	 
      	 
      	 
      
	
                    XII

                  	
                    Disclaimer
      of Warranties

                  	
                    15

                  
	 
      	 
      	 
      
	
                    XIII

                  	
                    Risk
      Allocation and Indemnification

                  	
                    16

                  
	 
      	 
      	 
      
	
                    XIV

                  	
                    Patent
      Validity

                  	
                    17

                  
	 
      	 
      	 
      
	
                    XV

                  	
                    Points
      of Contact

                  	
                    18

                  
	 
      	 
      	 
      
	
                    XVI

                  	
                    Notices

                  	
                    18

                  
	 
      	 
      	 
      
	
                    XVII

                  	
                    Dispute
      or Breach

                  	
                    19

                  
	 
      	 
      	 
      
	
                    XVIII

                  	
                    Termination
      or Modification

                  	
                    20

                  
	 
      	 
      	 
      
	
                    XIX

                  	
                    Assignment

                  	
                    22

                  
	 
      	 
      	 
      
	
                    XX

                  	
                    Governing
      Law

                  	
                    22

                  
	 
      	 
      	 
      

          

          

           

          
            
              
              

            

            
              
              

              
                

              

            

            
              
              

            

          

          
 

          
            	
                    XXI

                  	
                    Independent
      Entities

                  	
                    23

                  
	 
      	 
      	 
      
	
                    XXII

                  	
                    Effect
      of Partial Invalidity

                  	
                    23

                  
	 
      	 
      	 
      
	
                    XXIII

                  	
                    Nonwaiver

                  	
                    24

                  
	 
      	 
      	 
      
	
                    XXIV

                  	
                    Entire
      Agreement

                  	
                    24

                  
	 
      	 
      	 
      
	
                    XXV

                  	
                    Article
      Headings

                  	
                    24

                  
	 
      	 
      	 
      
	
                    XXVI

                  	
                    Counterparts

                  	
                    25

                  
	 
      	 
      	 
      
	
                    XXVII

                  	
                    Acceptance

                  	
                    25

                  
	 
      	 
      	 
      
	 
      	
                    Appendix

                  	
                    27

                  

          

          

        

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

      LICENSE
AGREEMENT

      

       

      PREAMBLE

      

      

      This
License Agreement (“AGREEMENT”) is entered into between the National Aeronautics
and Space Administration (NASA), an agency of the United States, hereinafter
referred to as LICENSOR, having its headquarters in Washington, D.C., and Nanotailor, Inc., a
corporation of the State of Texas, having its principal place of business at
701 Brazos, Suite 500, Austin,
TX 78701 hereinafter referred to as LICENSEE, as of the date of execution
of the last PARTY hereto.

      

      WITNESSETH:

      

      WHEREAS, under the authority
of 35 U.S.C. § 200 et seq., the U.S.
Department of Commerce has issued Patent Licensing Regulations (37 CFR Part 404)
specifying the terms and conditions upon which licenses may be granted for
inventions assigned to LICENSOR; and

      

      WHEREAS, LICENSOR is the
assignee of
two United States patents: U.S.
Patent No. 6,740,224 for an invention entitled “METHOD OF MANUFACTURING CARBON
NANOTUBES” which issued on MAY 25, 2004; and

      U.S. Patent No. 7,008,605 for
an invention entitled “METHOD
OF MANUFACTURING HIGH QUALITY CARBON NANOTUBES” which issued on MARCH 7, 2006
and,

      

      WHEREAS, LICENSEE, in
consideration of the grant of a license under U.S. Patent Nos. 6,740,224 and
7,008,605, will pay royalties, make all necessary capital investments, and
achieve PRACTICAL APPLICATION of the invention; and,

      

      WHEREAS, LICENSOR has
determined that the granting of a license to LICENSEE under U.S. Patent Nos.
6,740,224 and 7,008,605 will provide the necessary incentive for LICENSEE to
achieve the desired early PRACTICAL APPLICATION of the invention and the
granting of such license to LICENSEE will therefore be in the public
interest;

      

      NOW, THEREFORE, in accordance
with said Patent Licensing Regulations, and in consideration of the foregoing
and of the terms hereinafter contained in this AGREEMENT, the LICENSOR and
LICENSEE agree as set forth below:

      

       

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

      ARTICLE
I

      

       

      Definitions

      

      “ACCOUNTING
PERIOD” shall mean the period for which royalties are calculated.  For
this AGREEMENT, the period is every 12 months starting January 1 of each year,
except for the first ACCOUNTING PERIOD, which shall begin on the LICENSE
COMMENCEMENT DATE and end December 31, 2007.

      

      “BREACH”
shall mean (a) a violation or nonperformance by a PARTY of a MATERIAL term,
condition, covenant, or warranty herein, or (b) a misrepresentation made
hereunder or (c) a misrepresentation by LICENSEE to induce LICENSOR to enter
into this AGREEMENT (also see “MATERIAL”).

      

      “BREACHING
PARTY” shall mean the PARTY in BREACH, as used in Section 17.2.

      

      “GROSS
SALES” shall mean either the total amount invoiced by or for LICENSEE, and, in
the event that some or all of the amount invoiced by LICENSEE is in the form of
non-monetary remuneration, then the equivalent dollar value sum of such
remuneration, for all disposals i.e., (sales, uses, including uses by LICENSEE,
leases, transfers, etc.) of ROYALTY-BASE PRODUCTS for consideration determined
in, or as if in, an arm’s length transaction.

      

      “INSOLVENT”
shall mean that LICENSEE has either ceased to pay its debts (which may include
failure to pay royalty payments under this AGREEMENT) in the ordinary course of
business or cannot pay its debts as they fall due or is insolvent within the
meaning of the Federal Bankruptcy Code (11 U.S.C. § 101 (31)).

      

      “LICENSE
COMMENCEMENT DATE” shall mean the date that the last PARTY has executed this
AGREEMENT.

      

      “LICENSE
EXPIRATION DATE” shall mean the last day that this AGREEMENT is in
effect.

      

      “LICENSE
TERM” shall mean the period of time starting with the LICENSE COMMENCEMENT DATE
and ending with the LICENSE EXPIRATION DATE.

      

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

      “LICENSED
AREA” shall mean the United States.

      

      “LICENSED FIELD OR
EMBODIMENT(S)” shall mean Carbon Nanotube Production.

      

      “LICENSED
INVENTION” shall mean the invention defined by the claims of the LICENSED
PATENTS and as may be further limited by ARTICLE II.

      

      “LICENSED
PATENTS” shall mean United States Patent Nos. 6,740,224 and 7,008,605 and
shall include any corresponding reissue patents and modifications of said
LICENSED PATENTS by means of certificates of correction or reexamination
certificates.

      

      “MATERIAL,”
with respect to a particular matter (e.g., a BREACH), shall mean that the matter
is shown to effect adversely (a) the rights and benefits of the other PARTY
under this AGREEMENT; or (b) the ability of the other PARTY to perform its
obligations hereunder; and, in either case, to such a degree that a reasonable
person in the management of his or her own affairs would be more likely than not
to decline to enter into this AGREEMENT in view of the matter in
question.

      

      “NET
SALES” shall mean GROSS SALES, less allowances for returns and less (to the
extent separately stated, and not charged to the customer or others, on the
invoices):  (a) regular trade and quantity discounts; (b) insurance
and shipping charges from the point of origin; (c) duties, tariffs, and other
customs charges; and (d) sales, use, value added, and similar
taxes.  In the case of a sale or other disposition of ROYALTY-BASE
PRODUCTS which are transferred to a purchaser who does not deal at arm’s length,
or transferred or otherwise disposed of for other than monetary consideration
(including allocations to LICENSEE’s own beneficial use), NET SALES shall be
calculated in accordance with Section 7.5 of this AGREEMENT.

      

      “NONBREACHING
PARTY” shall mean the PARTY not in BREACH, as used in Section 17.2.

      

      “PARTY”
shall mean a party to this AGREEMENT.

      

      “PERSON”
shall mean a natural person; a corporation (for profit or not-for-profit); an
association; a partnership (general or limited); a joint venture; a trust; a
government or political department, subdivision, or agency; or any other
entity.

      

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

      “PRACTICAL
APPLICATION” shall mean, with respect to the LICENSED INVENTION, to reduce it to
practice and to commercialize it, i.e., to manufacture it in the case of a
composition or product, to practice it in the case of a process or method, or to
operate it in the case of a machine or system; and, in each case, under such
conditions as to establish:  (a) that a market for the LICENSED
INVENTION has been created, and to the extent practicable, that a market has
been created in the United States; (b) that it is being utilized; (c) that its
benefits are, to the extent permitted by law or Government regulations,
available to the public on reasonable terms; and (d) that market demand, at
least in the United States, shall be reasonably met.

      

      “ROYALTY-BASE
PRODUCTS” shall include the components of an item sold, used, leased,
transferred, or otherwise disposed of by LICENSEE or its SUBLICENSEES that is
covered by, included within or made by the LICENSED INVENTION.  For
purposes of this license, ROYALTY-BASE PRODUCTS include Carbon
Nanotubes.

      

      “SUBLICENSEE”
shall mean any PERSON who has the right, granted by LICENSEE, to make, use, or
sell the LICENSED INVENTION.

      

      “THIRD
PARTY” shall mean any PERSON other than the LICENSOR and the
LICENSEE.

      

       

      ARTICLE
II

      

      License
Grant

      

      2.1  LICENSOR hereby
grants to LICENSEE a terminable, royalty-bearing, nonexclusive license to
practice, i.e., to make, have made, use, offer to sell, sell, transfer, or
dispose of, the LICENSED INVENTION as limited to the LICENSED AREA and as may be
limited to a LICENSED FIELD OR EMBODIMENT(S), as defined in ARTICLE
I.

      

      2.2  LICENSOR, upon
request, will use reasonable efforts to grant LICENSEE, in accordance with 37
CFR Part 404, a license to practice any inventions assigned to LICENSOR, without
which license or licenses, the practice of the LICENSED INVENTION would result
in infringement.  The grant of said license or licenses shall be
limited, however, to the extent necessary to practice the LICENSED
INVENTION.  There will be no such grant where said inventions are
licensed exclusively.

      

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

      2.3  Notwithstanding
anything to the contrary in this AGREEMENT, LICENSEE shall take the license
granted in this ARTICLE II subject to any outstanding licenses or other rights
in THIRD PARTIES under agreements executed by LICENSOR before the LICENSE
COMMENCEMENT DATE.

      

      2.4  LICENSOR
reserves an irrevocable, royalty-free right to practice and have practiced the
LICENSED INVENTION, and any other inventions as provided in Section 2.2,
throughout the world by or on behalf of the Government of the United States and
on behalf of any foreign government pursuant to any existing or future treaty or
agreement with the United States.

      

       

      ARTICLE
III

      

      Sublicenses

      

      3.1  LICENSEE may
not grant any sublicenses under this AGREEMENT.

      

      ARTICLE
IV

      

      Term of
License

      

      4.1  Unless either
PARTY terminates this AGREEMENT in accordance with ARTICLE XVIII at an earlier
date, the license granted in ARTICLE II will be in effect for a LICENSE TERM
that is equal to the unexpired term of the last patent to be in effect of the
patent(s) encompassed under the definition of LICENSED
PATENTS.  Except as may be expressly provided otherwise herein or
agreed to in writing by LICENSOR, the license shall expire automatically at the
end of the LICENSE TERM without notice to LICENSEE.

       

       

      
 

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

       

      ARTICLE
V

      

       

      Practical
Application

      

      5.1  LICENSEE shall
achieve PRACTICAL APPLICATION of the LICENSED INVENTION within twelve (12) months of the
LICENSE COMMENCEMENT DATE and in accordance with the schedule set forth in the
APPENDIX to this AGREEMENT and incorporated into this
AGREEMENT.  LICENSEE shall notify LICENSOR within thirty (30) days of
achieving PRACTICAL APPLICATION that PRACTICAL APPLICATION has been achieved.
LICENSEE shall also provide evidence to verify the achievement.

      

      5.2  LICENSEE, once
PRACTICAL APPLICATION of the LICENSED INVENTION is achieved, shall thereafter
maintain it throughout the LICENSE TERM.

      

       

      ARTICLE
VI

      

      United States
Manufacture

      

      6.1  In achieving
and maintaining PRACTICAL APPLICATION of the LICENSED INVENTION, LICENSEE agrees
that any products embodying the LICENSED INVENTION or produced through the use
of the LICENSED INVENTION shall be reduced to practice and manufactured
substantially in the United States, in accordance with 35 U.S.C.
209(b).

      

      6.2  LICENSEE shall
make a bona fide attempt to use or sell the LICENSED INVENTION in the United
States.

      

      6.3  LICENSEE shall
promptly report to LICENSOR its discontinuance of making the benefits of the
LICENSED INVENTION available to the public.

      

       

      ARTICLE
VII

      

       

      Royalty and
Payment

      

      7.1  In
consideration of the license granted in ARTICLE II, LICENSEE shall remit to
LICENSOR a nonrefundable license fee in the amount of Twenty Thousand Dollars
($20,000.00), which shall be paid upon the execution of this AGREEMENT by
LICENSEE.

      

      7.2  LICENSEE agrees
to pay LICENSOR a running royalty of seven percent (7%) of the NET SALES of
ROYALTY-BASE PRODUCTS for each ACCOUNTING PERIOD.

      

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

      

      7.3  LICENSEE agrees
to pay LICENSOR a minimum royalty of Fifty
Thousand Dollars($50,000.00) for the ACCOUNTING PERIOD ending on December 31, 2008.  LICENSEE
agrees to pay LICENSOR a minimum royalty payment in the amount of Seventy Five
Thousand Dollars ($75,000.00) for the ACCOUNTING PERIOD ending on December 31, 2009. LICENSEE
agrees to pay LICENSOR a minimum royalty payment in the amount of One Hundred
and Twenty Five Thousand Dollars ($125,000.00) for the ACCOUNTING PERIOD ending
on December 31, 2010.
LICENSEE agrees to pay LICENSOR a minimum royalty payment in the amount of One
Hundred and Seventy Five Thousand Dollars ($175,000.00) for the ACCOUNTING
PERIOD ending on December 31,
2011 and for each ACCOUNTING PERIOD thereafter.

      

      7.4  The running
royalties specified in Sections 7.2 shall be credited against the minimum
royalty specified in Section 7.3.

      

      7.5  LICENSEE agrees
that in the event any ROYALTY-BASE PRODUCTS shall be sold, transferred, or
disposed of to a THIRD PARTY in a transaction that does not represent an arm’s
length transaction for purposes of resale by any THIRD PARTY, then the royalties
to be paid under this AGREEMENT for the ROYALTY-BASE PRODUCTS shall be based
upon the NET SALES of the ROYALTY-BASE PRODUCTS by such THIRD PARTY, rather than
upon the NET SALES of the LICENSEE.  Examples of transactions that do
not represent an arm’s length transaction includes sales, transfers or disposals
(a) to any type of organization or individual who owns a controlling interest in
LICENSEE by stock ownership or otherwise; (b) to any type of organization in
which LICENSEE shall own, directly or indirectly, a controlling interest by
stock ownership or otherwise; or (c) to any type of organization with which, or
individual with whom, LICENSEE, its stockholders, or associated companies shall
have any agreement, understanding, or arrangement (such as, among other things,
an option to purchase stock, an arrangement involving a division of profits, or
special rebates or allowances) without which agreement, understanding, or
arrangement, prices paid by such organization or individual for the ROYALTY-BASE
PRODUCTS would be higher than the NET SALES reported by LICENSEE, or if such
agreement, understanding, or arrangement results in extending to such
organization or individual lower prices for ROYALTY-BASE PRODUCTS than those
charged to outside concerns buying similar merchandise in similar amounts and
under similar conditions.

       

       

       

       

       

      
 

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

      

      7.6  Under this
AGREEMENT, ROYALTY-BASE PRODUCTS will be considered sold when invoiced, when
shipped, or upon receipt of payment, whichever occurs first.

      

      7.7  Royalties shall
be paid within thirty (30) days of the end of each ACCOUNTING
PERIOD.  Royalties shall be paid by check, denominated in United
States dollars, and made payable to the National Aeronautics and Space
Administration.  The check shall be mailed to LICENSOR at the address
set forth in ARTICLE XV of this AGREEMENT concurrently with the report required
in ARTICLE VIII of this AGREEMENT.  LICENSOR’s acceptance of any
royalty payment does not eliminate LICENSOR’s right to contest the accuracy of
such payment in the future.

      

      7.8  LICENSOR shall
assess interest, penalties, and administrative costs in accordance with the
Federal Claims Collections Standards, 31 C.F.R. §§ 900-904, on all payments due
LICENSOR which are not timely paid by LICENSEE.  In addition to these
charges, LICENSOR is authorized to charge to LICENSEE the costs of collection
and any associated reasonable attorney fees.

       

      

      

       

      ARTICLE
VIII

      

       

      Reports

      

      8.1  LICENSEE shall
submit to LICENSOR written reports within thirty (30) days of the end of each
ACCOUNTING PERIOD whether or not royalties are due.  Each report shall
be submitted concurrently with the royalties required by ARTICLE
VII.  To ensure that any proprietary information submitted by LICENSEE
is protected to the fullest extent of the law, LICENSEE should mark with a
proprietary notice any portions of the report that are considered proprietary to
LICENSEE.

       

       

       

       

      
        
          
          

        

        
          11

          
            

          

        

        
          
          

        

      

      

      8.2  Each report
shall include the following information:

      

      
        	
                (a)

              	
                With
      reference to the schedule set forth in the APPENDIX to this AGREEMENT, a
      narrative description of the steps being taken to reduce the LICENSED
      INVENTION to practice.

              
	 
      	 
      
	
                (b)

              	
                With
      reference to the schedule set forth in the APPENDIX to this AGREEMENT, a
      narrative description of the steps being taken to create a market demand
      for the LICENSED INVENTION, to commercialize the LICENSED INVENTION, and
      to meet market demand for the LICENSED INVENTION.

              
	 
      	 
      
	
                (c)

              	
                A
      narrative description of the ROYALTY-BASE PRODUCTS currently being offered
      for sale by LICENSEE and its SUBLICENSEES.  Copies of current
      sales brochures, promotional materials, and price lists shall be included
      with this description.

              
	 
      	 
      
	
                (d)

              	
                A
      list of the geographic locations at which the LICENSED INVENTION is being
      manufactured.

              
	
                 
      

              	 
      
	
                (e)

              	
                The
      number and type of ROYALTY-BASE PRODUCTS sold or disposed of by
      LICENSEE.

              
	 
      	 
      
	
                (f)

              	
                The
      number and type of ROYALTY-BASE PRODUCTS sold or disposed of by each
      SUBLICENSEE (if any).

              
	 
      	 
      
	
                (g)

              	
                The
      number and type of ROYALTY-BASE PRODUCTS sold or disposed of by each
      reseller of ROYALTY-BASE PRODUCTS under Section 7.5.

              
	 
      	 
      
	 
      	 
      
	
                (h)

              	
                LICENSEE’s
      GROSS SALES.

              
	 
      	 
      
	
                (i)

              	
                GROSS
      SALES for each SUBLICENSEE (if any).

              
	 
      	 
      
	
                (j)

              	
                GROSS
      SALES for each reseller of ROYALTY-BASE PRODUCTS under Section
      7.5.

              
	 
      	 
      
	
                (k)

              	
                LICENSEE’s
      NET SALES.

              
	 
      	 
      
	
                (l)

              	
                NET
      SALES for each SUBLICENSEE (if any).

              
	 
      	 
      
	
                (m)

              	
                NET
      SALES for each reseller of ROYALTY-BASE PRODUCTS under Section
      7.5.

              
	 
      	 
      
	
                (n)

              	
                The
      amount of royalties due LICENSOR.

              
	 
      	 
      

      

      8.3  Each report
shall include a certification by an officer of LICENSEE that the LICENSEE is
complying with the terms and conditions of this AGREEMENT and that the responses
to each part of Section 8.2 are accurate and complete.

      

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

      

      8.4  LICENSEE shall,
on an annual basis, submit to LICENSOR an audited balance sheet and an audited
income statement.  Internal audits are permissible, but LICENSOR
reserves the right to require an independent audit and additionally reserves the
right to approve of the auditor.

      

      8.5  A final report
shall be submitted to LICENSOR by LICENSEE within thirty (30) days after the
termination of this AGREEMENT.

      

       

      ARTICLE
IX

      

       

      Audit
Rights

      

      9.1  LICENSEE shall
keep full, true, and accurate records for the purpose of LICENSOR verifying
LICENSEE’s reports to LICENSOR under ARTICLE VIII, verifying LICENSEE’s royalty
payments to LICENSOR under ARTICLE VII, and for determining LICENSEE’s
activities in general under the AGREEMENT.  These records shall
include, but are not limited to, ledgers and journals of account, customer
orders, invoices, shipping documents, inventory records, computer records,
purchase orders, and tax records.  These records, as a whole, shall
include information which will allow, at a minimum, identification of suppliers,
customers, items sold or otherwise transferred, and/or services rendered, as
well as whether the LICENSEE is operating within the scope of its
license.

      

      9.2  The records
described in Section 9.1 shall be available for audit by LICENSOR, or by an
authorized representative of LICENSOR, at all reasonable times for the LICENSE
TERM and for three (3) calendar years thereafter.  In addition,
LICENSEE shall permit inspection by LICENSOR, or by an authorized representative
of LICENSOR, of LICENSEE’s assembly facilities and of LICENSEE’s inventory of
ROYALTY-BASE PRODUCTS, including parts, works-in-progress, and finished goods,
during any audit by LICENSOR.

      

      9.3  If LICENSOR, as
a result of an audit, discovers an underpayment of royalties that exceeds Two
Thousand Five Hundred Dollars ($2,500), then LICENSEE shall reimburse LICENSOR
for the cost of the audit, including all related costs of performing the audit
(e.g., travel, food, lodging, cost of professional services, etc.), in addition
to any penalties assessed pursuant to Section 7.8.

       

      

      
        
          
          

        

        
          13

          
            

          

        

        
          
          

        

      

       

      ARTICLE
X

      

       

      Marking

      

      10.1  LICENSEE and
all SUBLICENSEES shall mark all ROYALTY-BASE PRODUCTS, or products incorporating
ROYALTY-BASE PRODUCTS, in accordance with the statutes of the United States
relating to the marking of patented articles (see 35 U.S.C. §
287).  Such marking shall be accomplished by fixing on the article or
when, from the character of the article, this cannot be done, by fixing to it,
or to the package wherein one or more of the articles is contained, a label
including the notation “Licensed from the National Aeronautics and Space
Administration under (insert patent number).”  Such marking shall also
be included in all literature and/or advertising materials describing the
LICENSED INVENTION.

      

       

      ARTICLE
XI

      

       

      Use of the NASA
Name

      

      11.1  Except as
required by ARTICLE X, LICENSEE may use the name of LICENSOR, or the acronym
“NASA,” only in truthful statements concerning its relationship with
LICENSOR.  The letters ‘NASA’ may be used in such truthful statements
only if they are:

      

      
        	
                (a)

              	
                used
      in their normal typed or printed form;

              
	 
      	 
      
	
                (b)

              	
                the
      same size, color, and intensity as the rest of the words in a
      sentence;

              
	 
      	 
      
	
                (c)

              	
                not
      used in their stylized version as they appear in the NASA logotype or NASA
      insignia; and

              
	 
      	 
      
	
                (d)

              	
                not
      used to indicate that NASA endorses the LICENSEE's products, processes,
      etc.

              

      

       

       

      
 

      
        
          
          

        

        
          14

          
            

          

        

        
          
          

        

      

      11.2  Uses of the
letters ‘NASA’, other than those required by ARTICLE X or specified in Section
11.1, shall require the express written approval of
LICENSOR.  Approval by LICENSOR shall be based on applicable law
(i.e., 42 U.S.C. §§ 2459b, 2472(a), and 2473(c)(1); and 14 CFR § 1221.100 et seq.) and NASA policy
governing the use of the letters ‘NASA’ and the words ‘National Aeronautics and
Space Administration’ and shall not be unreasonably withheld.

      

      11.3 LICENSEE agrees to make
copies of its marketing literature available to LICENSOR so that LICENSOR can
determine that such use is in accordance with the terms of this
ARTICLE.

      

       

      ARTICLE
XII

      

       

      Disclaimer of
Warranties

      

      12.1  LICENSOR MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, AS TO ANY MATTER
WHATSOEVER.

      

      12.2  ALL
REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, INCLUDING BUT
NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE ARE EXCLUDED HEREUNDER.

      

      12.3  In particular,
nothing in this AGREEMENT shall be construed as:

      

      
        	
                (a)

              	
                A
      warranty or representation by LICENSOR as to the validity or scope of any
      LICENSED PATENT; or

              
	 
      	 
      
	
                (b)

              	
                A
      warranty or representation that anything made, used, sold, or otherwise
      disposed of under any license granted in this AGREEMENT is or will be free
      from infringement of any type, including patent infringement, copyright
      infringement, and trademark infringement; or

              
	 
      	 
      
	
                (c)

              	
                A
      requirement that LICENSOR shall file any patent application, secure any
      patent, or maintain any patent in force, other than the LICENSED PATENT;
      or

              
	 
      	 
      
	
                (d)

              	
                An
      obligation to bring or prosecute actions or suits against THIRD PARTIES
      for infringement; or

              
	 
      	 
      
	
                (e)

              	
                An
      obligation to furnish any manufacturing or technical information; or, if
      any such information is supplied, a warranty or representation that such
      information is accurate; or

              
	 
      	 
      
	
                (f)

              	
                Conferring
      a right to use in advertising, publicity or otherwise the name of any
      inventor of the LICENSED INVENTION or the NASA name, seal, insignia,
      logotype or any other adaptation without the prior written consent of
      LICENSOR (except as otherwise provided in ARTICLE XI);
  or

              
	 
      	 
      
	
                (g)

              	
                Precluding
      the export from the United States of ROYALTY-BASE PRODUCTS on which
      royalties shall have been paid as provided in ARTICLE VII, provided that
      the item can be exported under the export control laws of the United
      States; or

              
	 
      	 
      
	
                (h)

              	
                Granting
      by implication or estoppel, any licenses or other rights under any patent
      of LICENSOR or any other PERSON in the United States or any foreign
      country; or

              
	 
      	 
      
	
                (i)

              	
                Granting
      by implication, estoppel, or otherwise, any licenses or rights under
      patents or patent applications of LICENSOR other than the LICENSED
      INVENTION, regardless of whether such other patents or patent applications
      are dominant, subordinate, or an improvement to the invention or
      inventions as claimed, of the LICENSED PATENT or LICENSED PATENT
      APPLICATION, nor to other applications that did not claim the
      invention.

              
	 
      	 
      
	
                (j)

              	
                Conferring
      upon any PERSON (1) any immunity from or defenses under the antitrust
      laws, (2) any immunity from a charge of patent misuse, or (3) any immunity
      from the operation of Federal, State, or other
  law.

              

      

       

      
        
          
          

        

        
          15

          
            

          

        

        
          
          

        

      

      ARTICLE
XIII

      

      Risk Allocation and
Indemnification

      

      13.1  LICENSOR makes
no representation, extends no warranties of any kind, either express or implied,
and assumes no responsibility whatsoever with respect to use, sales, or other
disposition by LICENSEE or its vendees or other transferees of products
incorporating or made by the use of (a) the LICENSED INVENTION or (b)
information, if any, furnished under this AGREEMENT.

      

      13.2  LICENSEE shall
indemnify LICENSOR, its officers and employees, and hold them harmless against
all liabilities, demands, damages, expenses, or losses including, but not
limited to, attorney’s fees, court costs, and the like, arising (a) out of the
use by LICENSEE or its transferees of the LICENSED INVENTION or information
furnished under this AGREEMENT, or (b) out of any sale, use, or other
disposition by LICENSEE or its transferees of products, processes, or
compositions, made by use of such inventions or information.

      

      13.3  It shall be
the sole responsibility of the LICENSEE to ensure that any and all embodiments
of the LICENSED INVENTION are safe under all circumstances.

      

      13.4  Independent
of, severable from, and to be enforced independently of any other enforceable or
unenforceable provision of this AGREEMENT, other than as provided in Sections
13.1 and 13.2, or other than for infringement of one PARTY’s intellectual
property rights by another PARTY, (including any engagement in licensable
activities by licenses beyond the scope of the license provided by this
AGREEMENT), neither PARTY will be liable to the other PARTY (nor to any THIRD
PARTY claiming rights derived from the other PARTY’s rights) for incidental,
consequential, special, punitive, or exemplary damages of any kind, including
lost profits, loss of business, or other economic damage, and further including
injury to property, as a result of breach of any warranty or other term of this
AGREEMENT, regardless of whether the PARTY liable or allegedly liable was
advised, had reason to know, or in fact knew of the possibility
thereof.

       

       

       

      
 

      
        
          
          

        

        
          16

          
            

          

        

        
          
          

        

      

       

      ARTICLE
XIV

      

       

      Patent
Validity

      

      14.1  If, in any
proceeding in which the validity, infringement, or priority of invention of any
claim of the LICENSED PATENT to LICENSEE is in issue, a judgement or decree is
entered which becomes final (below referred to as an “final judgement”), the
construction placed upon any such claim by such final judgement shall thereafter
be followed, not only as to such claim but as to all claims to which such
construction applies, with respect to subsequently occurring acts.  If
such final judgement holds any claim invalid, LICENSEE shall be relieved
prospectively (a) from including in its reports ROYALTY-BASE PRODUCTS sold or
otherwise disposed of covered only by such claim or any broader claim to which
such final judgement is applicable, and (b) from the performance of those other
acts which may be required by this AGREEMENT only because of any such
claim.  However, if there are two or more conflicting final judgements
with respect to the same claim based on the same grounds or where the same
issues were raised, the decision of the higher tribunal shall be followed, but
if the tribunals be of equal dignity, then the decision more favorable to the
claim shall be followed.

      

      14.2  In the event
evidentiary material comes to the attention of the LICENSEE that, in the
judgement of the LICENSEE, bears on the validity or scope of any LICENSED
PATENT, the LICENSOR will in good faith discuss with the LICENSEE whether such
evidentiary material so affects the validity or scope of the LICENSED PATENT to
which it is asserted to apply that the terms of the license in respect to such
LICENSED PATENT should be modified.

      

      14.3  The LICENSEE,
after the LICENSE COMMENCEMENT DATE, may assert the invalidity of any claim in
any LICENSED PATENT, if coupled with or followed by:

      

      
        	
                (a)

              	
                Withholding,
      or notice of intention to withhold, or denial of obligation to pay,
      royalties otherwise payable under this AGREEMENT in respect to the
      LICENSEE’s operations under such claim; or

              
	 
      	 
      
	
                (b)

              	
                Initiation
      or participation in a suit challenging or denying the validity of such
      claim in reference to LICENSEE’s operations under this AGREEMENT, that
      may, at the option of the LICENSOR, be conclusively presumed to constitute
      LICENSEE’s termination, as of the earliest provable date of such
      withholding, notice, denial, initiation, or participation, of its
      AGREEMENT including its obligation for payment of royalties due from the
      date of the termination.

              

      

       

      
 

      
        
          
          

        

        
          17

          
            

          

        

        
          
          

        

      

      ARTICLE
XV

      

       

      Points of
Contact

      

      15.1  The following
PERSONS are designated as the points of contact for their respective PARTY and
are responsible for keeping this information current by providing updated
information as warranted.  These points of contact are the principal
representatives of the PARTIES involved in the performance of this
AGREEMENT.

      

      
        
          	
                  LICENSOR

                	
                  LICENSEE

                
	 
      	 
      
	
                  Name:  
      David
      Walker                                          

                	
                  Name: 
      _________________________________

                
	 
      	 
      
	
                  Title:    
      Chief Patent
      Counsel                            

                	
                  Title:   
      _________________________________

                
	 
      	 
      
	
                  Address: 
      NASA Goddard
      Space                     
      

                	
                  Address:
      _______________________________

                
	
                  Flight Center, Mail Code
      140.1                          
      

                	______________________________________
	
                  Greenbelt, Maryland
      20771                                
      

                	______________________________________
	 
      	 
      
	
                  Telephone
      No.:  301-286-7351                           
      

                	
                  Telephone
      No.: ___________________________

                
	 
      	 
      
	
                  Facsimile
      No.:  301-286-9502                             
      

                	
                  Facsimile
      No.:
____________________________

                

        

      

      

      

       

      ARTICLE
XVI

      

       

      Notices

      

      16.1  All notices
hereunder will be in writing and will be delivered and effective as
follows:

      

      
        	
                (a)

              	
                Every
      notice required or contemplated by this AGREEMENT to be given either PARTY
      may be delivered in person or may be sent by commercial courier or U.S.
      mail, addressed to the PARTY for whom it is intended, at the address
      specified in ARTICLE XV.

              
	 
      	 
      
	
                (b)

              	
                Any
      notice will be effective on the date that it is hand delivered or on the
      fifth business day after it was deposited with the commercial courier or
      the U.S. mail.

              
	 
      	 
      
	
                (c)

              	
                As
      used in this ARTICLE, a reference to a particular date means the date
      itself, if a business day, otherwise the first business day after the
      date.

              

      

      

       

      
        
          
          

        

        
          18

          
            

          

        

        
          
          

        

      

      ARTICLE
XVII

      

       

      Dispute or
Breach

      

      17.1  All disputes
concerning the interpretation or application of this AGREEMENT shall be
discussed mutually between the PARTIES.  Any disputes that are not
disposed of by mutual agreement shall be decided by the NASA Lead Counsel
Intellectual Property, or designee, who shall reduce the decision to writing and
mail or otherwise deliver a copy thereof to LICENSEE.  LICENSEE may
respond to such notice of a decision in accordance with the procedures set forth
in Section 18.8.

      

      17.2  In the event
of a BREACH of any provision of this AGREEMENT, the NONBREACHING PARTY shall
give the BREACHING PARTY notice describing the BREACH and stating that the
BREACHING PARTY has thirty (30) days after notice of the BREACH to cure the
BREACH or show cause why the AGREEMENT should not be terminated.

      

      17.3  If a provision
of this AGREEMENT sets forth a cure period for the BREACH in question other than
thirty (30) days, then that provision shall take precedence over the cure period
set forth in Section 17.2.

      

      17.4  No cure period
is required, except as may be otherwise provided in this AGREEMENT,
if:

      

      
        	
                (a)

              	
                this
      AGREEMENT sets forth specific deadline dates for the obligation allegedly
      breached; or

              
	 
      	 
      
	
                (b)

              	
                this
      AGREEMENT otherwise states that no cure period is required in connection
      with the termination in question.

              

      

      

      17.5  The BREACHING
PARTY will be deemed to have cured such BREACH if within the cure period it
takes steps reasonably adequate to alleviate any damage to the NONBREACHING
PARTY resulting from the BREACH and to prevent a similar future
BREACH.

       

      

      
        
          
          

        

        
          19

          
            

          

        

        
          
          

        

      

       

      ARTICLE
XVIII

      

       

      Termination or
Modification

      

      18.1  The PARTIES
may terminate or modify this AGREEMENT by mutual consent upon such terms as they
may agree in writing.

      

      18.2  Either PARTY
may terminate this AGREEMENT by failing to extend the LICENSE TERM, if an
extension is provided for in ARTICLE IV.

      

      18.3  Either PARTY
may terminate this AGREEMENT upon the discovery by one PARTY of any intentional
MATERIAL false statement or misrepresentation made or submitted by the other
PARTY which BREACHES any obligation under the terms of this AGREEMENT or upon
the discovery by one PARTY that the other PARTY has committed a MATERIAL breach
of a provision of the AGREEMENT.

      

      18.4  LICENSEE may
prospectively terminate this AGREEMENT upon ninety (90) days written notice to
LICENSOR.

      

      18.5  This AGREEMENT
may be terminated by LICENSOR if:

      

      
        	
                (a)

              	
                LICENSOR
      determines that LICENSEE has failed or will fail to achieve or maintain
      PRACTICAL APPLICATION of the LICENSED INVENTION as provided by ARTICLE
      V.

              
	 
      	 
      
	
                (b)

              	
                LICENSOR
      determines that LICENSEE has failed or will fail to reduce to practice or
      substantially manufacture the LICENSED INVENTION in the United States as
      provided by Section 6.1.

              
	 
      	 
      
	
                (c)

              	
                LICENSOR
      determines that LICENSEE has failed or will fail to meet market demand for
      the LICENSED INVENTION.

              
	 
      	 
      
	
                (d)

              	
                LICENSEE
      fails to pay royalties or submit reports as provided by ARTICLES VII and
      VIII.

              
	 
      	 
      
	
                (e)

              	
                LICENSOR
      determines that such action is necessary to meet the requirements for
      public use specified by Federal regulations issued after the date of the
      license and such requirements are not reasonably satisfied by
      LICENSEE.

              
	 
      	 
      
	
                (f)

              	
                LICENSEE
      commits a BREACH of a covenant contained in this
  AGREEMENT.

              

      

       

       

      
 

      
        
          
          

        

        
          20

          
            

          

        

        
          
          

        

      

      18.6  LICENSOR may
terminate this AGREEMENT if LICENSEE becomes INSOLVENT.  LICENSEE must
notify LICENSOR within thirty (30) days after becoming
INSOLVENT.  LICENSEE’s failure to conform to this requirement shall be
deemed a MATERIAL, incurable BREACH.

      

      18.7  LICENSEE must
promptly inform LICENSOR of its intention to file a voluntary petition in
bankruptcy or of another’s communicated intention to file an involuntary
petition in bankruptcy.  LICENSOR may terminate this AGREEMENT upon
receiving notice of intention to file.  LICENSEE’s filing without
conforming to this requirement shall be deemed a MATERIAL, pre-petition
incurable BREACH.

      

      18.8  Before
LICENSOR unilaterally modifies or terminates this AGREEMENT for any cause,
LICENSOR will deliver to LICENSEE and all SUBLICENSEES of record a written
notice stating LICENSOR’s intention to modify or terminate the AGREEMENT and the
reasons therefor.  LICENSEE and SUBLICENSEES of record will be allowed
thirty (30) days after: (a) such notice to remedy any BREACH of the AGREEMENT or
show cause why the AGREEMENT should not be unilaterally modified or terminated;
or, (b) such notice of a decision regarding a dispute, rendered in accordance
with Section 17.1, to rebut such decision.  A response to a notice of
modification or termination or to a notice of a dispute decision should be
addressed to the General Counsel, National Aeronautics and Space Administration,
Washington, DC  20546.  The General Counsel will render a
determination based on the LICENSEE’s response within a reasonable
time.  Absent any response from LICENSEE to the notice regarding the
modification, termination, and/or dispute decision, the decision by the Lead
Counsel Intellectual Property will be final and/or the AGREEMENT will be
unilaterally modified or will terminate, effective thirty-one (31) days from the
notice of modification, termination, or dispute decision, with no right to
appeal under Section 18.9.

       

       

       

      
 

      
        
          
          

        

        
          21

          
            

          

        

        
          
          

        

      

      18.9  LICENSEE may
appeal in writing to the NASA Administrator, any determination rendered by the
General Counsel in accordance with Section 18.8, within thirty (30) days of
notice of such determination.  The notice of appeal and all supporting
documentation should be addressed to the Administrator, National Aeronautics and
Space Administration, Washington, DC  20546.  LICENSEE shall
be afforded an opportunity to be heard and to offer evidence in support of its
appeal.  The decision on the appeal shall be made by the NASA
Administrator or designee, which shall be the final agency decision from which
there will be no further right of administrative appeal.  Nothing in
this Article shall be interpreted as precluding actions at law.

      

      18.10  If no action
is taken under Section 18.9, then the determination rendered by the General
Counsel shall become final within thirty-one (31) days after delivery of the
notice of such determination.

      

      18.11  All royalties
and reports due up to and including the date of termination of this AGREEMENT
are due within thirty (30) days of the date of termination.

      

      

      ARTICLE
XIX

      

      Assignment

      

      19.1  Upon written
approval by LICENSOR, LICENSEE may assign this AGREEMENT provided that LICENSEE
submits to LICENSOR, in advance, a written request for permission to grant the
assignment, information that NASA considers necessary to evaluate the proposed
assignment, and a copy of the proposed assignment.  If LICENSOR
approves the assignment as being consistent with the Government’s interests, the
PARTIES and the assignee will be required to execute a novation
agreement.  At a minimum, the novation agreement will provide that
LICENSEE waives all rights under the license, the assignee assumes all
obligations under the AGREEMENT, and that LICENSOR recognizes the assignee as
the successor in interest to the AGREEMENT.

      

       

      ARTICLE
XX

      

       

      Governing
Law

      

      20.1  This AGREEMENT
will be interpreted and enforced in accordance with United States federal
law.

       

      

      
        
          
          

        

        
          22

          
            

          

        

        
          
          

        

      

       

      ARTICLE
XXI

      

       

      Independent
Entities

      

      21.1  The Parties
are separate and independent entities.  Except as may be expressly and
unambiguously provided in this AGREEMENT, no partnership or joint venture is
intended to be created by this AGREEMENT, nor any principal-agent or
employer-employee relationship.

      

      21.2  Except to the
extent expressly provided in this AGREEMENT, neither PARTY has, and neither
PARTY shall attempt to assert, the authority to make commitments for or to bind
the other PARTY to any obligation.

       

      

       

      ARTICLE
XXII

      

       

      Effect of Partial
Invalidity

      

      22.1  If any one or
more of the provisions of this AGREEMENT should be ruled wholly or partly
invalid or unenforceable by a court or other government body of competent
jurisdiction, and as long as the fundamental objectives of the AGREEMENT can be
carried out, then:

      

      
        	
                (a)

              	
                the
      validity and enforceability of all provisions of this AGREEMENT not ruled
      to be invalid or unenforceable will be unaffected;

              
	 
      	 
      
	
                (b)

              	
                the
      provision(s) held wholly or partly invalid or unenforceable will be deemed
      to be amended, and the court or other government body is authorized to
      reform the provision(s), to the minimum extent necessary to render them
      valid and enforceable in conformity with the PARTIES’ intent as manifested
      herein; and

              
	 
      	 
      
	
                (c)

              	
                if
      the ruling, and/or the controlling principle of law or equity leading to
      the ruling, is subsequently overruled, modified, or amended by
      legislative, judicial, or administrative action, then the provision(s) in
      question, as originally set forth in this AGREEMENT, will be deemed to be
      valid and enforceable to the maximum extent permitted by the new
      controlling principle of law or
equity.

              

      

       

      

      
        
          
          

        

        
          23

          
            

          

        

        
          
          

        

      

       

      

       

      ARTICLE
XXIII

      

       

      Nonwaiver

      

      23.1  The failure of
either PARTY at any time to require performance by the other PARTY of any
provisions of this AGREEMENT shall in no way affect the right of such PARTY to
require future performance of that provision.  Any waiver by either
PARTY of any BREACH of any provision of this AGREEMENT shall not be construed as
a waiver of any continuing or succeeding BREACH of such provision, a waiver of
the provision itself, or a waiver of any right under this
AGREEMENT.

      

       

      ARTICLE
XXIV

      

       

      Entire
Agreement

      

      24.1  Except as may
be expressly provided otherwise herein, this AGREEMENT constitutes the entire
agreement between the PARTIES concerning the subject matter
thereof.  No prior or contemporaneous representations, inducements,
promises, or agreements, oral or otherwise, between the PARTIES with reference
thereto will be of any force or effect.  This AGREEMENT may only be
modified by written agreement of the PARTIES.

      

       

      ARTICLE
XXV

      

       

      Article
Headings

      

      25.1  The Article
Headings contained in this AGREEMENT are for reference purposes only and shall
not in any way control the meaning or interpretation of this
AGREEMENT.

      

      
        
          
          

        

        
          24

          
            

          

        

        
          
          

        

      

       

      ARTICLE
XXVI

      

       

      Counterparts

      

      26.1  This AGREEMENT
may be executed in separate counterparts, each of which so executed and
delivered shall constitute an original, but all such counterparts shall together
constitute one and the same instrument.  Any such counterpart may
comprise one or more duplicates or duplicate signature pages, any of which may
be executed by less than all of the PARTIES, provided that each PARTY executes
at least one such duplicate or duplicate signature page.  The PARTIES
stipulate that a photostatic copy of an executed original will be admissible in
evidence for all purposes in any proceeding as between the PARTIES.

      

      

       

      ARTICLE
XXVII

      

       

      Acceptance

      

      27.1  In witness
whereof, each PARTY has caused this AGREEMENT to be executed by its duly
authorized representatives:

      

      

      
        
          	
                  LICENSOR:

                	
                  LICENSEE:

                
	 
      	 
      
	
                  National
      Aeronautics and

                	
                  Nanotailor,
      Inc..

                
	
                  Space
      Administration

                	 
      
	 
      	 
      
	 
      	 
      
	 
      	 
      
	 
      	 
      
	
                  By: 
      Michael C.
      Wholley                                
      

                	
                  By: 
      _______________________________

                
	
                  NASA
      General Counsel

                	
                  CEO

                
	 
      	 
      
	 
      	 
      
	 
      	 
      
	________________________________	___________________________________
	
                  Date

                	
                  Date

                

        

      

      
 

       

      
        
          
          

        

        
          25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]